What is the recommended management for chronic constipation?

Management of Chronic Constipation

Start with polyethylene glycol (PEG) 17 g daily as first-line pharmacological therapy for chronic idiopathic constipation, as it has the strongest evidence base with moderate certainty and a strong recommendation from the 2023 AGA-ACG guidelines. 1

Stepwise Treatment Algorithm

Step 1: Initial Pharmacological Management

• Polyethylene glycol (PEG) 17 g daily is the primary recommended treatment with a strong recommendation and moderate certainty of evidence 1
• PEG demonstrates durable response over 6 months and is cost-effective at $10-45 monthly 1
• Common side effects include abdominal distension, loose stool, flatulence, and nausea, but these are generally well-tolerated 1
• Dose can be titrated based on symptom response with no clear maximum dose 1

Step 2: Adjunctive or Alternative First-Line Options

Fiber supplementation can be considered, particularly for patients with low dietary fiber intake, though evidence is weaker:

• Psyllium is the only fiber supplement with reasonable evidence (conditional recommendation, low certainty) 1
• Start with 14 g per 1,000 kcal intake per day 1
• Ensure adequate hydration as flatulence is a common side effect 1
• Can be used alone for mild constipation or in combination with PEG 1

Magnesium oxide 400-500 mg daily is another option (conditional recommendation, very low certainty):

• Avoid in patients with renal insufficiency due to hypermagnesemia risk 1
• Studies used doses of 1,000-1,500 mg daily, so titration upward is possible 1
• Cost-effective at <$50 monthly 1

Step 3: Second-Line Therapy for OTC Failures

Lactulose 15 g daily (conditional recommendation, very low certainty):

• Reserve for patients who fail or are intolerant to over-the-counter therapies 1
• Only osmotic agent studied in pregnancy 1
• Bloating and flatulence are dose-dependent and may limit use 1

Step 4: Prescription Therapies for Refractory Cases

When over-the-counter options fail, escalate to prescription medications with strong evidence:

Prucalopride 1-2 mg daily (strong recommendation, moderate certainty):

• 5-HT4 receptor agonist with prokinetic effects 1
• Can be used as replacement or adjunct to OTC agents 1
• May provide additional benefit for abdominal pain 1
• Side effects include headache, abdominal pain, nausea, and diarrhea 1
• Cost approximately $563 monthly 1

Intestinal secretagogues are alternative prescription options:

• Linaclotide 72-145 μg daily (maximum 290 μg daily) at $523 monthly 1
• Plecanatide 3 mg daily at $526 monthly 1
• Lubiprostone 24 μg twice daily at $374 monthly 1
• All may benefit abdominal pain but can cause diarrhea leading to discontinuation 1

Step 5: Rescue Therapy

Stimulant laxatives for short-term use or rescue only:

• Bisacodyl 5 mg daily (maximum 10 mg daily) 1
• Senna 8.6-17.2 mg daily 1
• Recommended for short-term use only due to unknown long-term safety and efficacy 1
• Side effects include cramping, abdominal discomfort, and potential electrolyte imbalance with prolonged use 1

Critical Implementation Considerations

Cost and accessibility matter in real-world practice:

• PEG and fiber are the most cost-effective options at <$50 monthly 1
• Prescription medications cost $374-563 monthly and may require prior authorization 1
• Generic formulations are not available for all prescription options 1

Common pitfalls to avoid:

• Do not use stimulant laxatives as first-line chronic therapy due to unknown long-term safety 1
• Avoid magnesium oxide in renal insufficiency patients 1
• Do not assume all fiber supplements are equal—only psyllium has reasonable evidence 1
• Ensure adequate hydration with fiber supplementation to prevent worsening symptoms 1

When to perform diagnostic testing:

• Perform anorectal testing to evaluate for defecatory disorders in patients who do not respond to over-the-counter agents 2, 3
• Consider colonic transit studies if initial therapies fail 2
• Biofeedback therapy may be beneficial for defecatory disorders 4, 2

Evidence Quality Context

The 2023 AGA-ACG guidelines represent the highest quality and most recent evidence available [1-1]. The strongest recommendation (strong, moderate certainty) is for PEG, making it the clear first-line choice 1. Most other recommendations carry conditional strength with low to very low certainty, reflecting limited high-quality evidence in this field 1. The European guidelines from 2020 similarly support PEG as having the highest level of evidence among osmotic laxatives 3.